B C · Business · CA ·
Xenon halts depression study enrollment after adverse events reported
The Globe and Mail · Business
Published · Updated
- Xenon Pharmaceuticals paused enrollment in a late-stage trial testing its drug as an antidepressant treatment.
- The drug triggered adverse events in some patients, mostly mild or moderate in severity.
- Xenon stock fell approximately 30 percent Friday, closing at US$39.91 per share.
- The company is simultaneously pursuing FDA approval for the same drug to treat epilepsy.
Read it at the source
The Globe and Mail↗We link out rather than republish. The reporting belongs to the publications above; the summary and the search data on this page are ours.
